ArticleLeukemia & lymphoma2015

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma.

Farrukh T Awan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.